Non-small-cell lung cancer
Conditions
Interventions
Paclitaxel at a dose of 200mg/m2 and bevacizumab 15mg/kg were administrated every 21 days until disease progression, unacceptable toxicity, patient refusal, alternate treatment, or investigator'
s decision to remove patient from study.
Sponsors
First Department of Internal Medicine, Shinshu University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Non-squamous non-small-cell lung cancer with histologic or cytologic evidence. 2) Clinical stage IV 3) Previously treated with more than one systemic chemotherapy 4) Age >=20, <75 5) ECOG performance status <=2 6) Adequate organ functions like below WBC >=3000/mm3 Neutrophil count >=1500/mm3 Platelet count >=100000/mm3 Serum creatinine <=1.2mg/dl Total bilirubin <=1.5mg/dl AST <=80IU/l ALT <=80IU/l PaO2 >=60Torr or SpO2 >90% 7) Written informed consent
Exclusion criteria
Exclusion criteria: 1) Previously treated with paclitaxel and / or bevacizumab 2) Patients with brain metastasis 3) Patients with hemoptysis 4) Patients receiving therapeutic anticoagulation 5) Patients with complications like below Active infection Acute myocardial infarction during recent 6 months or the other severe heart disease Uncontrollable diabetes mellitus Uncontrollable hypertension Active psychological disease 6) Hypersensitivity to paclitaxel and / or bevacizumab 7) Active concomitant malignancy 8) Pregnancy or lactation 9) Inappropriate patients for this study judged by the physicians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Three-months progression free rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall response rate Overall survival Toxicity | — |
Countries
Japan
Contacts
Public ContactShintaro Kanda
Shinshu University School of Medicine First Department of Internal Medicine
Outcome results
None listed